Claims for Patent: 9,295,669
✉ Email this page to a colleague
Summary for Patent: 9,295,669
Title: | Combination therapy for proliferative disorders |
Abstract: | The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation. |
Inventor(s): | Dhingra; Kapil (Sparta, NJ), Higgins; Brian (Fresh Meadows, NY), Kolinsky; Kenneth (Bloomingdale, NJ), Lee; Richard J. (New York, NY), Lestini; Brian (Union City, NJ), Packman; Kathryn (Bloomfield, NJ), Su; Fei (Paramus, NJ) |
Assignee: | Hoffman La-Roche Inc. (Nutley, NJ) |
Application Number: | 13/313,042 |
Patent Claims: | 1. A method of treating a patient suffering from a proliferative disorder, comprising administering to the patient: (A) a first component which comprises, as an active
agent, propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]amide}, or a pharmaceutically acceptable salt thereof; and (B) a second component which comprises, as an active agent, peginterferon
alfa-2a; wherein said propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]amide} is administered in an amount of from about 1700 mg/day to about 2100 mg/day, wherein said amount is about 25 mg/kg,
and said peginterferon alfa-2a is administered in an amount of from about 180 .mu.g/week to about 630 .mu.g/week, and wherein said proliferative disorder is selected from the group consisting of: colorectal cancer, melanoma, and thyroid cancer, wherein
said cancer involves a tumor comprising b-Raf having the V600E mutation.
2. A method according to claim 1 wherein said patient is a human. 3. A method according to claim 1 wherein said proliferative disorder is melanoma containing the V600E b-Raf mutation. 4. A method according to claim 1 wherein propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]amide}, or a pharmaceutically acceptable salt thereof, is substantially in amorphous form. 5. A method according to claim 1 wherein propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]amide}, or a pharmaceutically acceptable salt thereof, is in amorphous form. 6. A method according to claim 1 wherein propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]amide}, or a pharmaceutically acceptable salt thereof, is contained in a solid molecular complex formed with hydroxypropyl methyl cellulose acetate succinate such that it is immobilized in its amorphous form. 7. A method according to claim 6 wherein the amounts of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]amide}, or a pharmaceutically acceptable salt thereof, are hydroxypropyl methyl cellulose acetate succinate in said complex are in a ratio of from about 1:9 to about 5:5, respectively. 8. A method according to claim 6 wherein the amounts of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]amide}, or a pharmaceutically acceptable salt thereof, and hydroxypropyl methyl cellulose acetate succinate in said complex are in a ratio of about 3:7, respectively. 9. A method according to claim 6 wherein said first component comprises a blend wherein about 97% by weight of the blend is said complex and about 3% by weight of the blend is silicon dioxide. 10. A method according to claim 6 wherein said first component comprises a suspension of said complex in a pharmaceutically acceptable carrier. 11. A method according to claim 1 wherein said first component comprises a tablet comprising a solid molecular complex of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]amide}, or a pharmaceutically acceptable salt thereof, and hydroxypropyl methyl cellulose acetate succinate. |
Details for Patent 9,295,669
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 10/16/2002 | ⤷ Try a Trial | 2030-12-14 |
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 01/07/2004 | ⤷ Try a Trial | 2030-12-14 |
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 09/29/2011 | ⤷ Try a Trial | 2030-12-14 |
Hoffmann-la Roche Inc. | PEGASYS COPEGUS COMBINATION PACK | peginterferon alfa-2a and ribavirin | 125083 | 06/04/2004 | ⤷ Try a Trial | 2030-12-14 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.